Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan

    ... change in hemoglobin (Hb) level, the withdrawal of transfusion and corticosteroids, the change of renal function, and overall ... An increase in Hb and a high rate of transfusion independence were observed, especially in patients with platelet ...

    Research Article last updated 11/02/2016 - 10:39am.

  2. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan

    ... change in hemoglobin (Hb) level, the withdrawal of transfusion and corticosteroids, the change of renal function, and overall ... An increase in Hb and a high rate of transfusion independence were observed, especially in patients with platelet ...

    Research Article last updated 08/15/2016 - 9:10am.

  3. Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis

    ... INTRODUCTION: Multiple studies show that transfusion independence (TI) in myelodysplastic syndrome (MDS) has a positive impact ...

    Research Article last updated 06/23/2016 - 10:11am.

  4. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... the efficacy and safety of lenalidomide in RBC transfusion-dependent patients with International Prognostic Scoring System ... The primary end point was the rate of RBC transfusion independence (TI) ≥ 8 weeks. Secondary end points were RBC-TI ≥ 24 ...

    Research Article last updated 07/18/2016 - 10:30am.

  5. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po

    ... hematologic improvement in 28 % of patients and RBC transfusion independence sustained for 56 days in 47 % of patients with baseline ...

    Research Article last updated 06/23/2016 - 10:17am.

  6. Clinical Utility of Lenalidomide in the Treatment of Myelodysplastic Syndromes

    ... with anemia were treated with red blood cell transfusion and red blood cell growth factors. The first clinical trial ... trial found 67% achieved red blood cell transfusion independence . Red blood cell transfusion independence was achieved in a ...

    Research Review last updated 05/02/2016 - 9:12am.

  7. Effectiveness of lenalidomide in patients over 75 vs. patients under 75 with RBC transfusion-dependent low/int-1-risk MDS and del5q

    ... who were treated with lenalidomide achieved sustained independence from RBC transfusions.  Moreover, most patients saw either ... treatment affords many patients a sustained RBC transfusion independence and a significant cytogenetic response. ... younger patients, as reflected by equivalent rates of RBC transfusion-independence, cytogenetic response, and AML progression. While ...

    Research Review last updated 05/02/2016 - 9:32am.

  8. Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

    ... the goals of maintaining donor hematopoiesis and transfusion independence while decreasing early and late complications of HCT for DC. ...

    Clinical Trial last updated 04/27/2016 - 8:49am.

  9. Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

    ... to a single course of ATG (non-robust responders), even when transfusion-independence is achieved, predicts a worse prognosis than when robust ...

    Clinical Trial last updated 04/25/2016 - 2:47pm.

  10. Myelodysplastic syndromes: What do hospitalists need to know?

    ... are candidates for supportive therapy, which includes transfusion support, use of growth factors, and antibiotics as needed.   ... without this deletion.  It can produce transfusion independence and complete remissions in lower-risk MDS patients. In ...

    Research Review last updated 05/02/2016 - 9:21am.